HRP20240701T1 - Pripravci za uporabu u liječenju hipertenzije - Google Patents

Pripravci za uporabu u liječenju hipertenzije Download PDF

Info

Publication number
HRP20240701T1
HRP20240701T1 HRP20240701TT HRP20240701T HRP20240701T1 HR P20240701 T1 HRP20240701 T1 HR P20240701T1 HR P20240701T T HRP20240701T T HR P20240701TT HR P20240701 T HRP20240701 T HR P20240701T HR P20240701 T1 HRP20240701 T1 HR P20240701T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
dose
use according
indapamide
telmisartan
Prior art date
Application number
HRP20240701TT
Other languages
English (en)
Croatian (hr)
Inventor
Anthony Rodgers
Stephen Macmahon
Original Assignee
The George Institute for Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The George Institute for Global Health filed Critical The George Institute for Global Health
Publication of HRP20240701T1 publication Critical patent/HRP20240701T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20240701TT 2017-01-25 2018-01-23 Pripravci za uporabu u liječenju hipertenzije HRP20240701T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762450324P 2017-01-25 2017-01-25
EP22188172.5A EP4101454B1 (en) 2017-01-25 2018-01-23 Compositions for use in the treatment of hypertension

Publications (1)

Publication Number Publication Date
HRP20240701T1 true HRP20240701T1 (hr) 2024-09-27

Family

ID=62979058

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230267TT HRP20230267T1 (hr) 2017-01-25 2018-01-23 Pripravci za liječenje hipertenzije
HRP20240701TT HRP20240701T1 (hr) 2017-01-25 2018-01-23 Pripravci za uporabu u liječenju hipertenzije

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230267TT HRP20230267T1 (hr) 2017-01-25 2018-01-23 Pripravci za liječenje hipertenzije

Country Status (21)

Country Link
US (6) US10322117B2 (enExample)
EP (6) EP4635566A2 (enExample)
JP (3) JP2020506180A (enExample)
KR (4) KR20250107955A (enExample)
CN (4) CN116327958A (enExample)
AU (2) AU2018213147B2 (enExample)
CA (1) CA3051374A1 (enExample)
DK (2) DK3573620T3 (enExample)
ES (2) ES2940316T3 (enExample)
FI (2) FI3573620T3 (enExample)
HR (2) HRP20230267T1 (enExample)
HU (2) HUE067617T2 (enExample)
LT (2) LT4101454T (enExample)
MX (2) MX2019008813A (enExample)
PL (2) PL4101454T3 (enExample)
PT (2) PT4101454T (enExample)
RS (2) RS64042B1 (enExample)
RU (1) RU2019126749A (enExample)
SI (2) SI3573620T1 (enExample)
TW (5) TWI825279B (enExample)
WO (1) WO2018138578A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
FI3573620T3 (fi) 2017-01-25 2023-03-25 The George Inst For Global Health Koostumuksia kohonneen verenpaineen hoitamiseksi
JP2021536443A (ja) * 2018-08-25 2021-12-27 シーアールディー ファーマシューティカルズ インコーポレイティド 高血圧治療をサーカディアンリズムと同期させる
CN111789843A (zh) 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CN113616651B (zh) * 2020-05-08 2023-12-29 深圳奥萨制药有限公司 一种复方降压药物组合物及其应用
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
EP4574148A1 (en) 2023-12-20 2025-06-25 KRKA, d.d., Novo mesto Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension
WO2025226012A1 (ko) 2024-04-23 2025-10-30 신풍제약주식회사 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
CA2406077C (en) 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
WO2005099700A1 (en) 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
KR100582347B1 (ko) 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
KR20090057538A (ko) * 2007-12-03 2009-06-08 박사룡 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물
CN101450211A (zh) * 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN101966191A (zh) 2009-07-14 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和替米沙坦的复方制剂
CN101618215A (zh) 2009-08-16 2010-01-06 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN102869360B (zh) 2010-05-03 2015-03-25 东生华制药股份有限公司 治疗高血压的医药组合物及方法
EP2575808A1 (en) * 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) * 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) * 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
CN102327272B (zh) 2011-07-14 2013-08-14 海南锦瑞制药股份有限公司 一种口服固体药用组合物及其制备方法
US10918612B2 (en) * 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
US9839644B2 (en) * 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
CN106074418A (zh) 2016-06-23 2016-11-09 南京华宽信息咨询中心 一种治疗高血压的苯磺酸氨氯地平片及其制备方法
CN106310278A (zh) * 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
FI3573620T3 (fi) 2017-01-25 2023-03-25 The George Inst For Global Health Koostumuksia kohonneen verenpaineen hoitamiseksi
US20250205210A1 (en) 2017-01-25 2025-06-26 The George Institute for Global Health Compositions for the treatment of hypertension
MX2021001043A (es) * 2018-07-26 2021-04-12 The George Inst For Global Health Composiciones para el tratamiento de hipertension.

Also Published As

Publication number Publication date
EP4620524A2 (en) 2025-09-24
KR20240096848A (ko) 2024-06-26
PT3573620T (pt) 2023-03-20
JP2023063282A (ja) 2023-05-09
KR20250052479A (ko) 2025-04-18
EP3573620A4 (en) 2020-11-25
ES2981657T3 (es) 2024-10-09
US12285415B2 (en) 2025-04-29
SI4101454T1 (sl) 2024-10-30
EP4101454B1 (en) 2024-04-10
TW202508572A (zh) 2025-03-01
KR20190127691A (ko) 2019-11-13
JP2020506180A (ja) 2020-02-27
US20200397770A1 (en) 2020-12-24
BR112019015368A2 (pt) 2020-03-10
CN120585831A (zh) 2025-09-05
TWI825279B (zh) 2023-12-11
EP3573620A1 (en) 2019-12-04
PL4101454T3 (pl) 2024-07-29
FI3573620T3 (fi) 2023-03-25
CN110545819A (zh) 2019-12-06
EP4101454A1 (en) 2022-12-14
FI4101454T3 (fi) 2024-06-10
CN116327958A (zh) 2023-06-27
EP4374915A2 (en) 2024-05-29
AU2018213147A1 (en) 2019-09-19
HUE067617T2 (hu) 2024-11-28
RS65701B1 (sr) 2024-07-31
AU2018213147B2 (en) 2023-08-31
US12102623B2 (en) 2024-10-01
RU2019126749A3 (enExample) 2021-08-30
RS64042B1 (sr) 2023-04-28
DK4101454T3 (da) 2024-06-17
JP2025010535A (ja) 2025-01-21
AU2023274064A1 (en) 2023-12-14
EP4609913A2 (en) 2025-09-03
WO2018138578A1 (en) 2018-08-02
LT3573620T (lt) 2023-04-11
US11478462B2 (en) 2022-10-25
US20190343818A1 (en) 2019-11-14
EP4609913A3 (en) 2025-11-12
TW202421198A (zh) 2024-06-01
EP4374915A3 (en) 2024-07-31
TW202023619A (zh) 2020-07-01
US12465599B2 (en) 2025-11-11
MX2023004366A (es) 2023-05-03
DK3573620T3 (da) 2023-03-20
PT4101454T (pt) 2024-06-17
SI3573620T1 (sl) 2023-05-31
LT4101454T (lt) 2024-07-25
US20250312325A1 (en) 2025-10-09
RU2019126749A (ru) 2021-02-26
US20230087834A1 (en) 2023-03-23
US20180243278A1 (en) 2018-08-30
KR20250107955A (ko) 2025-07-14
CA3051374A1 (en) 2018-08-02
TW201831204A (zh) 2018-09-01
TW202319049A (zh) 2023-05-16
MX2019008813A (es) 2020-02-12
US10322117B2 (en) 2019-06-18
PL3573620T3 (pl) 2023-04-24
HUE061444T2 (hu) 2023-08-28
EP3573620B1 (en) 2022-12-14
EP4635566A2 (en) 2025-10-22
US10799487B2 (en) 2020-10-13
CN119386015A (zh) 2025-02-07
TWI852279B (zh) 2024-08-11
US20230381161A1 (en) 2023-11-30
HRP20230267T1 (hr) 2023-06-09
ES2940316T3 (es) 2023-05-05
EP4620524A3 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
HRP20240701T1 (hr) Pripravci za uporabu u liječenju hipertenzije
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
HRP20161277T1 (hr) Pripravci za liječenje centralno posredovane mučnine i povraćanja
FI3435996T3 (fi) Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
JP2018527305A5 (enExample)
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
JP2019536816A5 (enExample)
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
MD4877B1 (ro) Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
RU2017113827A (ru) Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения
JP2012097034A5 (enExample)
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
JP2017515858A5 (enExample)
WO2011035343A3 (en) Phentermine liquid dosage form
RU2017115341A (ru) Фармацевтическая композиция, содержащая бета-блокатор и ингибитор ангиотензинпревращающего фермента
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent